Gaman AM, Gaman GD. Deficiency Of Antithrombin III (AT III) - Case Report and Review of the Literature. Curr Health Sci J. 2014 Apr-Jun. 40 (2):141-3. [Medline]. [Full Text].
Yilmaz S, Gunaydin S. Inherited risk factors in low-risk venous thromboembolism in patients under 45 years. Interact Cardiovasc Thorac Surg. 2015 Jan. 20 (1):21-3. [Medline].
Beauchamp NJ, Pike RN, Daly M, et al. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood. 1998 Oct 15. 92(8):2696-706. [Medline].
Kuhle S, Lane DA, Jochmanns K, et al. Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism. Thromb Haemost. 2001 Oct. 86(4):1007-11. [Medline].
Di Minno MN, Dentali F, Lupoli R, Ageno W. Mild antithrombin deficiency and risk of recurrent venous thromboembolism: a prospective cohort study. Circulation. 2014 Jan 28. 129 (4):497-503. [Medline].
Sokol J, Timp JF, le Cessie S, et al. Mild Antithrombin Deficiency and Risk of Recurrent Venous Thromboembolism: Results from the MEGA follow-up Study. J Thromb Haemost. 2018 Jan 28. [Medline].
Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med. 1975 Jan 16. 292(3):146-51. [Medline].
Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood. 2001 Oct 15. 98(8):2423-31. [Medline].
Rodgers GM. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update. Thromb Haemost. 2009 May. 101(5):806-12. [Medline].
Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs. 2007. 67(10):1429-40. [Medline].
Lenz B, Samardzija M, Drenjancevic D, Zibar D, Samardzija M, Milostic-Srb A. The investigation of hereditary and acquired thrombophilia risk factors in the development of complications in pregnancy in Croatian women. J Matern Fetal Neonatal Med. 2016. 29 (2):264-9. [Medline].
Rheaume M, Weber F, Durand M, Mahone M. Pregnancy-Related Venous Thromboembolism Risk in Asymptomatic Women With Antithrombin Deficiency: A Systematic Review. Obstet Gynecol. 2016 Apr. 127 (4):649-56. [Medline].
[Guideline] Institute for Clinical Systems Improvement (ICSI). Venous thromboembolism. ICSI. 2007 Jun. [Full Text].
Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003 Aug. 90(2):235-44. [Medline].
Vossen CY, Conard J, Fontcuberta J, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost. 2005 Mar. 3(3):459-64. [Medline].
Young G, Albisetti M, Bonduel M, et al. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation. 2008 Sep 23. 118(13):1373-82. [Medline].
Andrews M, Monagale PT, Brooker L. Thromboembolic Complications During Infancy and Childhood. London: BC Decker, Inc. Hamilton; 2000. 321-60.
ATryn, Antithrombin (recombinant) [package insert]. GTC Biotherapeutics, inc. 2009. Available at [Full Text].
Bucur SZ, Levy JH, Despotis GJ, et al. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion. 1998 May. 38(5):481-98. [Medline].
Corral J, Hernandez-Espinosa D, Soria JM, Gonzalez-Conejero R, Ordonez A, Gonzalez-Porras JR. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood. 2007 May 15. 109(10):4258-63. [Medline].
de Galan-Roosen AE, Kuijpers JC, Rosendaal FR, Steegers EA, van Beers WA, Ponjee GA. Maternal and paternal thrombophilia: risk factors for perinatal mortality. BJOG. 2005 Mar. 112(3):306-11. [Medline].
Feero WG. Genetic thrombophilia. Prim Care. 2004 Sep. 31(3):685-709, xi. [Medline].
Fyfe A, Tait RC. Antithrombin-a for the prophylaxis of venous thrombosis in congenital antithrombin deficiency. Expert Rev Hematol. 2009 Oct. 2(5):499-507. [Medline].
Haire WD. Antithrombin III in hematopoietic stem cell transplantation. Semin Thromb Hemost. 1997. 23(6):591-601. [Medline].
Haire WD, Ruby EI, Stephens LC, et al. A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 1998. 4(3):142-50. [Medline].
Hayek S, Kenet G, Lubetsky A, et al. Does thrombophilia play an aetiological role in Legg-Calve-Perthes disease?. J Bone Joint Surg Br. 1999 Jul. 81(4):686-90. [Medline].
Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Hematol. 2010 Dec. 85(12):947-50. [Medline].
Kurnik K, Kosch A, Strater R, Schobess R, Heller C, Nowak-Gottl U. Recurrent thromboembolism in infants and children suffering from symptomatic neonatal arterial stroke: a prospective follow-up study. Stroke. 2003 Dec. 34(12):2887-92. [Medline].
Langlois NJ, Wells PS. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review. Thromb Haemost. 2003 Jul. 90(1):17-26. [Medline].
Luxembourg B, Delev D, Geisen C, Spannagl M, Krause M, Miesbach W, et al. Molecular basis of antithrombin deficiency. Thromb Haemost. 2011 Apr. 105(4):635-46. [Medline].
Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs. 2007. 67(10):1429-40. [Medline].
Medical Economics, ed. Physicians' Desk Reference. 54th ed. Thomson PDR; 2000. 735-6. [Full Text].
Medical Economics, ed. Physicians' Desk Reference. 55th ed. Thomson PDR; 2001. 899.
Mitsuguro M, Sakata T, Okamoto A, et al. Usefulness of antithrombin deficiency phenotypes for risk assessment of venous thromboembolism: type I deficiency as a strong risk factor for venous thromboembolism. Int J Hematol. 2010 Oct. 92(3):468-73. [Medline].
Muszbek L, Bereczky Z, Kovacs B, Komaromi I. Antithrombin deficiency and its laboratory diagnosis. Clin Chem Lab Med. 2010 Dec. 48 Suppl 1:S67-78. [Medline].
Nagaraja D, Christopher R, Tripathi M. Plasma antithrombin III deficiency in ischaemic stroke in the young. Neurol India. 1999 Jun. 47(2):155-6. [Medline].
Ota K, Akizawa T, Hirasawa Y, et al. Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol Dial Transplant. 2003 Aug. 18(8):1623-30. [Medline].
Pal N, Kertai MD, Lakshminarasimhachar A, Avidan MS. Pharmacology and clinical applications of human recombinant antithrombin. Expert Opin Biol Ther. 2010 Jul. 10(7):1155-68. [Medline].
Picard V, Nowak-Göttl U, Biron-Andreani C, Fouassier M, Frere C, Goualt-Heilman M. Molecular bases of antithrombin deficiency: twenty-two novel mutations in the antithrombin gene. Hum Mutat. 2006 Jun. 27(6):600. [Medline].
Schinzel H, Weilemann LS. Antithrombin substitution therapy. Blood Coagul Fibrinolysis. 1998 Nov. 9 Suppl 3:S17-21; discussion S21-2. [Medline].